RNAZ Stock Summary and Trading Ideas (Transcode Therapeutics | NASDAQ:RNAZ)

TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Transcode Therapeutics trades on the NASDAQ stock market under the symbol RNAZ.

As of February 6, 2025, RNAZ stock price climbed to $11.85 with 10,076,880 million shares trading.

RNAZ has a beta of 4.24, meaning it tends to be more sensitive to market movements. RNAZ has a correlation of 0.07 to the broad based SPY ETF.

RNAZ has a market cap of $8.25 million. This is considered a Sub-Micro Cap stock.

Last quarter Transcode Therapeutics reported $0 in Revenue and -$5.28 earnings per share. This fell short of revenue expectation by $-300,000 and exceeded earnings estimates by $10.89.

In the last 3 years, RNAZ traded as high as $81,312.09 and as low as $2.66.

RNAZ has underperformed the market in the last year with a return of -37.6%, while the SPY ETF gained +24.2%. In the last 3 month period, RNAZ fell short of the market, returning -29.1%, while SPY returned +5.2%. However, in the most recent 2 weeks RNAZ has outperformed the stock market by returning +239.5%, while SPY returned -0.3%.

RNAZ support price is $7.43 and resistance is $10.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNAZ shares will trade within this expected range on the day.